Company Registry

JAAN Biotherapeutics LLC (AKA:JAAN (LIFE) Biotherapeutics )
Profile last edited on: 12/30/2021

New class of therapies to treat cardiovascular diseases
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6331 Nancy Ridge Drive Suite 204
San Diego, CA 92121
   (858) 869-3564
Multiple Locations:   
Congressional District:   52
County:   San Diego

Public Profile

Jaan Biotherapeutics, LLC is a private company using proprietary technology to develop novel therapies to activate the cardiac regeneration process in diseased hearts. The technology manipulates microRNAs to activate an endogenous cardiac muscle regeneration process which has been shut down in the adult human heart during evolution. JBT's is developing a cardiac muscle regeneration therapy currently focused on ischemic heart disease. The therapy, based on a Salk institute patent with UCSD confirming studies, inhibits 4 miRs to activate the endogenous cardiac muscle regeneration process suppressed in adult humans in the evolution process.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 1 NIH $321,085
Viral Delivered Cardiac Regeneration
2017 1 NIH $240,750
MicroRNA Inhibition for Cardiac Regeneration in Ischemia
2017 1 NIH $225,000
Oligonucleotide Inhibition for Cardiac Regeneration in Ischemia

Key People / Management

  Bhawanjit K Brar -- Founder and Chief Executive Officer

  Joseph Hansen -- Advisor

  Kirk L Peterson -- Professor of Medicine, Division of Cardiovascular Medicine, Director Emeritus, S

SBIR firms in the news

There are no news available.